Sameera Ezzat
Overview
Explore the profile of Sameera Ezzat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Alfaar A, Hassan D, Bawazir M, Elsanabary Z, Ezzat S, Elsayed Y
J Glaucoma
. 2025 Jan;
34(3):216-223.
PMID: 39792813
Prcis: Guardian education level and frequency of surgical interventions are key determinants of knowledge in primary congenital glaucoma, highlighting the need for targeted educational strategies. Objective: Management of congenital glaucoma...
2.
Mosbeh A, Abdelmaguid W, Ezzat S, Kohla M, Sultan M, Abdel-Rahman M
Asian Pac J Cancer Prev
. 2023 Sep;
24(9):3165-3168.
PMID: 37774068
Objective: Study the frequency of codon 7 (c.747 G>T, p. R249S) mutation associated with Aflatoxin B1 (AFB1) exposure in Egyptian patients with hepatocellular carcinoma (HCC). Methods: We utilized restriction fragment...
3.
Lupo P, Chambers T, Mueller B, Clavel J, Dockerty J, Doody D, et al.
Int J Cancer
. 2023 Sep;
154(3):434-447.
PMID: 37694915
Although recent studies have demonstrated associations between nonchromosomal birth defects and several pediatric cancers, less is known about their role on childhood leukemia susceptibility. Using data from the Childhood Cancer...
4.
Ezzat S, Gamkrelidze I, Osman A, Gomaa A, Roushdy A, Esmat G, et al.
Liver Int
. 2023 Apr;
43(7):1417-1426.
PMID: 37073160
Background & Aims: Egypt used to have one of the highest prevalences of HCV infection worldwide. The Egyptian Ministry of Health launched a national campaign for the detection and management...
5.
El-Kafrawy S, Abbas A, Oelkrug C, Tahoon M, Ezzat S, Zumla A, et al.
Front Immunol
. 2023 Feb;
14:1065353.
PMID: 36742328
Antibiotic resistant bacteria are a growing threat to global health security. Whilst the emergence of antimicrobial resistance (AMR) is a natural phenomenon, it is also driven by antibiotic exposure in...
6.
Ezzat S, Biga R, Kozlakidis Z
Biosaf Health
. 2022 Aug;
4(5):290-292.
PMID: 35910333
Biobanking facilities are well established in high-income settings, where substantial funding has been invested in infrastructure. In contrast, such facilities are much less developed in resource-restricted settings. However, low-and middle-income...
7.
Medhat M, El-Kassas M, Karam-Allah H, Al Shafie A, Abd-Elsalam S, Moustafa E, et al.
Arab J Gastroenterol
. 2022 Jun;
23(3):165-171.
PMID: 35690556
Background And Study Aims: Currently, there is no therapy approved for COVID-19. We evaluated the efficacy and safety of sofosbuvir/ledipasvir and nitazoxanide for the treatment of patients with COVID-19 infection....
8.
Schraw J, Bailey H, Bonaventure A, Mora A, Roman E, Mueller B, et al.
Int J Cancer
. 2022 May;
151(7):1013-1023.
PMID: 35532209
Increasing evidence suggests that breastfeeding may protect from childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). However, most studies have limited their analyses to any breastfeeding, and only...
9.
Kamal L, Ramadan A, Farraj S, Bahig L, Ezzat S
Saudi Pharm J
. 2022 Mar;
30(5):508-518.
PMID: 35287313
Background: Throughout the time of the global pandemic of SARS-CoV-2 virus, there has been a compelling necessity for the development of effective antiviral agents and prophylactic vaccines to limit the...
10.
Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi M, Youssef N, et al.
Eur Geriatr Med
. 2021 Oct;
10(2):295-302.
PMID: 34652758
Background And Aim: Old people with chronic hepatitis C (HCV) were considered a difficult-to-treat category with more frequent adverse events until recently. Interferon-free direct-acting antivirals (DAAs) improved treatment adherence and...